PetMed Express Earnings Call Shows Painful Turnaround
Petmed Express ((PETS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
PetMed Express’ latest earnings call painted a mixed picture of a company making real operational progress while still wrestling with sharp financial deterioration. Management stressed that internal controls, technology and costs are moving in the right direction, and that second‑half trends are stabilizing. Yet the steep revenue decline and sizable full‑year loss underscore the scale of the turnaround challenge ahead.
Sequential Q4 Improvement and Narrower Net Loss
Q4 net sales fell 15.6% year over year to $42.8 million, but importantly rose sequentially from Q3, marking the first sequential Q4 increase since fiscal 2024. The quarterly net loss narrowed to $4.1 million, or $0.19 per diluted share, compared with a $11.6 million loss, or $0.56 per share, in the same period last year.
Q4 Gross Margin Expansion
Gross profit in Q4 came in at $13.9 million, translating to a gross margin of 32.6% versus 29.9% a year earlier. The 270‑basis‑point improvement was driven largely by the settlement of a New York sales tax liability, giving a one‑time boost to profitability in the quarter.
Cost Savings and Leaner Cost Structure
PetMed exited underperforming vendor relationships that are expected to generate roughly $6.1 million in annualized savings. General and administrative expense in Q4 declined 8.6% year over year to $11.4 million from $12.5 million, reflecting ongoing cost optimization efforts aimed at resetting the company’s expense base.
Remediated Material Weaknesses and Governance Actions
Management reported full remediation of three previously disclosed material weaknesses, covering tone at the top, complex accounting areas and income taxes. The company also changed external auditors to Baker Tilly U.S. LLP and brought its regulatory filings up to date, bolstering governance and financial reporting credibility.
Technology and Operational Modernization
The company rolled out a new enterprise resource planning system, a new fraud prevention platform and upgraded call center technology. Management framed these investments as a modernization of the tech stack that should reduce operational risk and ultimately support better customer experiences and higher retention.
Operational and Customer ‘Green Shoots’
In the second half, PetMed saw early signs of operational improvement, including better trends in prescription medication sales and in both prescription and nonprescription food categories. The company also noted rising autoship sign‑ups and improved customer‑facing service metrics, alongside higher employee satisfaction scores.
Solid Liquidity and Debt‑Free Balance Sheet
As of March 31, 2026, PetMed held $21.4 million in cash and cash equivalents and carried no debt on its balance sheet. Management highlighted this liquidity and lack of leverage as key supports for ongoing transformation initiatives, giving the company breathing room despite current losses.
Strategic B2B Expansion Opportunities
To diversify revenue and leverage its pharmacy infrastructure, PetMed is pursuing business‑to‑business opportunities, including white‑label pharmacy fulfillment. A Master Services Agreement with Rural King is intended to bring its capabilities to new customers and potentially create higher‑margin, recurring B2B revenue streams over time.
Sharp Full‑Year Revenue Decline
For the full year, net sales dropped to $179.0 million from $227.0 million, a steep 21.1% decline. Management attributed the bulk of this falloff to weaker prescription medication sales, signaling ongoing demand challenges in what remains the company’s core product category.
Large Full‑Year Net Loss and One‑Off Charges
PetMed posted a full‑year net loss of $57.3 million, or $2.74 per diluted share, versus a $6.3 million loss, or $0.30 per share, a year ago. The result was heavily affected by nonrecurring items, including a $26.7 million noncash goodwill impairment, a $2.1 million wholesale inventory write‑down and $4.5 million in legal, professional and severance costs.
Adjusted EBITDA Slide
Adjusted EBITDA deteriorated to negative $15.4 million for the year, compared with a positive $0.7 million in the prior period. In Q4, adjusted EBITDA loss widened to $2.8 million from a $1.9 million loss a year earlier, showing that profitability on a cash‑flow basis remains under significant pressure.
Ongoing Weakness in Core Prescription Sales
Management acknowledged that declines in prescription medication sales were the main driver of both quarterly and full‑year revenue contraction. This persistent weakness in the core business highlights the urgency of improving customer retention and rebuilding demand in PetMed’s primary franchise.
Nonrecurring Costs and Failed Wholesale Initiative
Several one‑time costs weighed on results, including the goodwill impairment, inventory write‑down and investigation‑related expenses. The $2.1 million inventory write‑down in Q3 stemmed from a wholesale initiative that proved an unsuccessful departure from PetMed’s core business model, prompting a strategic refocus.
Advertising and Depreciation Add Expense Pressure
Advertising expense in Q4 increased to $5.8 million from $5.4 million, an uptick partly attributed to how vendor co‑op funds were presented. Depreciation and amortization rose to $2.4 million from $2.1 million, reflecting elevated investment in systems and infrastructure that also adds near‑term cost pressure.
Rebuffed Takeover Interest
PetMed revealed it received two nonbinding acquisition proposals in December 2025, valuing the company at $4.00 to $4.25 per share. After review, the board chose not to proceed, keeping the company independent while acknowledging that takeover interest could persist and create distractions for management.
Guidance and Focus on Stabilization and EBITDA Recovery
Instead of specific fiscal 2027 targets, management offered directional guidance centered on turning operational fixes into financial traction. The focus is on operational excellence, better customer retention and expansion of B2B and white‑label channels such as the Rural King partnership, with an emphasis on stabilizing revenue and driving EBITDA recovery rather than providing precise forecasts.
The earnings call portrayed a company in active repair mode, pairing tighter controls, cost cuts and technology upgrades with a candid view of deep revenue and profit challenges. Investors will be watching whether early “green shoots,” B2B initiatives and a clean, debt‑free balance sheet can translate into sustained top‑line stabilization and a credible path back to positive earnings.
